Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618982 | 0.85 | ALDH1A1 (0.61) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL4065474 | 0.84 | ADRB1 (0.53) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL3457200 | 0.79 | FAAH (0.43) | ALDH1A1HTR7MAPT | |
| SCHEMBL4071775 | 0.79 | ADRB1 (0.62) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL4291189 | 0.78 | ADRB1 (0.72) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL9706402 | 0.78 | ALDH1A1 (0.42) | ADRB1ALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL4072207 | 0.77 | ADRB1 (0.50) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL4565387 | 0.76 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2LMNAKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL10536215 | 0.76 | ADRB1 (0.50) | ADRB1ALDH1A1LMNAAKR1C3TSHR | |
| SCHEMBL11029799 | 0.76 | TRPA1 (0.41) | ADRB1ALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2529619-B1 | Treating neurological disorders | BIOGEN MA INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2529619-A2 | Treating neurological disorders | Biogen Idec MA Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120183542-A1 | TREATING NEUROLOGICAL DISORDERS | BIOGEN IDEC MA INC. | 2012-07-19 | — | — | US | disclosed |
| EP-2332408-A1 | Treating neurological disorders | Biogen Idec MA Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20090124993-A1 | TREATING NEUROLOGICAL DISORDERS | BIOGEN IDEC MA INC. | 2009-05-14 | — | — | US | disclosed |
| EP-1859277-A2 | TREATING NEUROLOGICAL DISORDERS | Biogen Idec MA Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070111932-A1 | Method of enhancing and/or inducing neuronal migration using erythropoietin | STEM CELL THERAPEUTICS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070100001-A1 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20060234912-A1 | Methods for modulating neuronal responses | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-10-19 | — | — | US | disclosed |
| WO-2006089095-A2 | TREATING NEUROLOGICAL DISORDERS | BIOGEN IDEC MA INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-5786390-A | ENZYME INHIBITORS OF ENZYME MONOAMINE OXIDASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1998-07-28 | — | — | US | disclosed |
| US-5744500-A | ADMINISTERING TO TREAT BRAIN ISCHEMIA OR STROKE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-04-28 | — | — | US | disclosed |
| EP-0828485-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | Teva Pharmaceutical Industries, Inc. (IL) | 1998-03-18 | — | — | EP | disclosed |
| EP-0812190-A4 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMA (IL) | 1998-03-04 | — | — | EP | disclosed |
| EP-0812190-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-12-17 | — | — | EP | disclosed |
| US-5599991-A | PARKINSON*S DISEASE; PSYCHOLOGICAL DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 1997-02-04 | — | — | US | disclosed |
| WO-1996037199-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-11-28 | — | — | WO | disclosed |
| US-5532415-A | MONOAMINE OXIDASE INHIBITORS; PARKINSON'S DISEASE, NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-07-02 | — | — | US | disclosed |
| US-5519061-A | MONOAMINE OXIDASE INHIBITORS, PARKINSON'S DISEASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-05-21 | — | — | US | disclosed |
| WO-1995011016-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100001-A1 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | PNMT, DRD3, SNCA | ADRB1 166/4885ALDH1A1 357/4885HPGD 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.